Venture-capital backed Biolex could be sold if it doesn’t find a drug-development partner, the firm’s chief financial officer told The Triangle Business Journal.

In a report published Friday, Dale Sander said: “At a minimum, we would hope to bring on partners.”

Intersouth Partners in Durham is an investor in Biolex.

Read the full story here.

Get the latest news alerts: Follow WRAL Tech Wire at Twitter.